Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1

NCT01234012 is registered in ClinicalTrials.gov with ImmunoFrontier, Inc. as lead sponsor.

NCT NCT01234012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01234012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1
Lead sponsor
ImmunoFrontier, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
March 31, 2014
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor